Why Prometheus will have little effect on Myriad
The US Supreme Court today granted cert in Association for Molecular Pathology v Myriad Genetics, vacating the judgment and remanding the case to the Federal Circuit
This is in light of last week''s ruling in Mayo v Prometheus, in which the Court found the diagnostic method patents owned by Prometheus invalid.
Lawyers told Managing IP it''s unlikely Prometheus would lead the Federal Circuit to change its...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.